NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

CSV download of the complete patent data set.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset the Search Filters to go back to the initial display of all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
NIAID E-037-2016-0-US-11 Attenuated RSV Vaccine Strains In Which The NS1 And/or NS2 Genes Have Been Shifted To Promoter-distal Positions US CON 17/183,227 11918638 Issued PDF
NHLBI E-090-2020-0-PCT-02 NK CELLS OR T CELLS EXPRESSING HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND METHODS OF USE PCT PCT PCT/US2021/019288 Expired
NHLBI E-090-2020-0-CN-04 NK CELLS OR T CELLS EXPRESSING HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND METHODS OF USE CN National Stage 202180030182.5 Pending
NHLBI E-090-2020-0-EP-05 NK CELLS OR T CELLS EXPRESSING HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND METHODS OF USE EP National Stage 21711990.8 Pending
NHLBI E-090-2020-0-HK-01 NK CELLS OR T CELLS EXPRESSING HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND METHODS OF USE HK EP 62023067864.6 Pending
NIDA E-053-2016-1-EP-06 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS; METHOD OF MAKING; AND USE THEREOF EP DIV 21158632.6 Pending
NHLBI E-090-2020-0-IL-06 NK CELLS OR T CELLS EXPRESSING HEMATOPOIETIC GROWTH FACTOR RECEPTORS AND USE FOR TREATING CANCER IL National Stage 295888 Pending
NCI E-265-2015-0-SA-20 T CELL RECEPTORS RECOGNIZING HLA-CW8 RESTRICTED MUTATED KRAS` SA DIV 521421309 Pending
NCATS E-072-2021-0-US-01 FUNCTIONAL BRAIN REGION-SPECIFIC NEURAL SPHEROIDS AND METHODS OF USE US 63/151,698 Abandoned
NIAID E-020-2020-0-PCT-02 EPSTEIN-BARR VIRUS MONOCLONAL ANTIBODIES AND USES THEREOF PCT PCT PCT/US2021/018836 Expired
NIAID E-020-2020-0-EP-03 EPSTEIN-BARR VIRUS MONOCLONAL ANTIBODIES AND USES THEREOF EP National Stage 21712309.0 Pending
NCATS E-168-2019-0-PCT-02 A Highly Efficient Astrocyte Differentiation Protocol For Human Pluripotent Stem Cells PCT PCT PCT/US2021/018659 Expired
NIAID E-045-2021-0-US-01 Novel Compositions Of Matter Comprising Stabilized Coronavirus Antigens And Their Use US 63/200,194 Abandoned
NIAMS E-244-2020-0-US-01 SARS-CoV-2 Neutralizing Nanobodies US 63/151,530 Abandoned
NCI E-046-2019-0-US-07 Non-aggregating Heptamethine Cyanine Fluorophores For In Vivo Imaging US CON 17/179,217 11746086 Issued PDF
NCI E-139-2018-0-US-03 WATER SOLUBLE NOVEL CYANINE FLUOROPHORE WITH TUNABLE PROPERTIES BETWEEN NEAR IR AND SWIR REGION FOR IN VIVO IMAGING US National Stage 17/269,517 11465993 Issued PDF
NEI E-057-2020-0-PCT-02 METHODS AND SYSTEMS FOR PREDICTING RATES OF PROGRESSION OF AGE-RELATED MACULAR DEGENERATION PCT PCT PCT/US2021/018589 Expired
NHGRI E-177-2015-0-US-05 CANCER DETECTION METHODS US DIV 17/179,298 Pending
NEI E-057-2020-0-EP-05 METHODS AND SYSTEMS FOR PREDICTING RATES OF PROGRESSION OF AGE-RELATED MACULAR DEGENERATION EP National Stage 21711144.2 Pending
NEI E-164-2018-3-EP-04 INTRAOCULAR DELIVERY OF GENE THERAPY EXPRESSION VECTORS EP National Stage 19756444.6 Pending
NEI E-057-2020-0-AU-03 METHODS AND SYSTEMS FOR PREDICTING RATES OF PROGRESSION OF AGE-RELATED MACULAR DEGENERATION AU National Stage 2021224660 Pending
NEI E-057-2020-0-CA-04 METHODS AND SYSTEMS FOR PREDICTING RATES OF PROGRESSION OF AGE-RELATED MACULAR DEGENERATION CA National Stage 3177173 Pending
NICHD E-003-2014-0-US-12 MONOCLONAL ANTIBODIES THAT SPECIFICALLY BIND TO MATRILIN 3 AND THEIR USE US CON 17/177,644 11680093 Issued PDF
NIDDK E-132-2018-1-US-02 PURINE AND PYRIMIDINE NUCLEOTIDES AS ECTO-5'-NUCLEOTIDASE INHIBITORS US National Stage 17/269,094 Abandoned
CC E-228-2009-0-US-10 System And Method Of Integrated Biopsy And Therapy US CON 17/176,218 Pending
NCI E-029-2021-0-US-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST CD22 US 63/149,795 Abandoned
NIAID E-214-2021-0-US-01 Self-assembling Nanoparticles Based On Amphiphilic Peptides US 63/149,996 Abandoned
NCI E-162-2014-0-US-10 Human Monoclonal Antibodies (mAbs) Against EphA4 As Candidate Therapeutics US DIV 17/175,879 Pending
NHLBI E-222-2022-8-US-01 Tissue Cutting Systems and Methods US CIP 17/148,616 Pending
NEI E-077-2018-0-US-04 METHODS OF METABOLIC REGULATION OF MITOCHONDRIA FOR TREATING NEURAL INJURY AND NEUROLOGICAL DISORDERS US National Stage 17/268,203 12011426 Issued PDF
NCCIH E-081-2020-0-PCT-02 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN PCT PCT PCT/US2021/017780 Expired
NCI E-031-2020-0-GB-12 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION GB National Stage 2211733.7 Pending
NCI E-031-2020-0-CN-06 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION CN National Stage 202180014038.2 Pending
NCCIH E-081-2020-0-EP-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN EP National Stage 21710729.1 Pending
NCI E-031-2020-0-EP-07 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION EP National Stage 21710730.9 Pending
NCI E-031-2020-0-TW-03 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION TW ORD 110105194 Pending
NCI E-074-2020-1-TW-02 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION TW ORD 110105193 Pending
NCI E-074-2020-1-PCT-01 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12V MUTATION PCT PCT COMB PCT/US2021/017852 Expired
NCI E-031-2020-0-PCT-02 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION PCT PCT PCT/US2021/017794 Expired
NCI E-031-2020-0-ZA-21 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION ZA National Stage 2022/08853 Pending
NCI E-031-2020-0-RU-23 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION RU National Stage 2022124004 Pending
NCI E-031-2020-0-KR-10 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION KR National Stage 2022-7031175 Pending
NCCIH E-081-2020-0-KR-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN KR National Stage 10-2022-7031665 Pending
NCI E-031-2020-0-SG-11 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION SG National Stage 11202251837Y Pending
NCI E-031-2020-0-MX-19 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION MX National Stage MX/a/2022/009654 Pending
NCCIH E-081-2020-0-MX-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN MX National Stage MX/a/2022/009914 Pending
NCI E-031-2020-0-JP-09 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION JP National Stage 2022-548811 Pending
NCCIH E-081-2020-0-JP-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN JP National Stage 2022-548411 Pending
NCI E-031-2020-0-CA-05 HLA CLASS I-RESTRICTED T CELL RECEPTORS AGAINST RAS WITH G12D MUTATION CA National Stage 3168015 Pending
NCCIH E-081-2020-0-CN-01 MARGARIC ACID DECREASES PIEZO2-MEDIATED MEDIATED PAIN CN National Stage 202180015900.1 Pending